OCUGEN, INC.

Description: Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations for gene therapy for the treatment of ocular disease, such as Stargardt Disease; Pharmaceutical preparations for gene therapy for the treatment of Stargardt Disease

Description: Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations for gene therapy for the treatment of ocular disease, such as Stargardt Disease; Pharmaceutical preparations for gene therapy for the treatment of Stargardt Disease

Description: Pharmaceutical preparations for gene therapy for the treatment of retinal diseases; Online advertising and marketing services in the field of ophthalmology; On-line advertising and marketing services; Ophthalmology services; Providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; Providing on-line information, news and commentary in the field of health and wellness relating to ophthalmology; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Biotechnology research; Product research; Scientific research; Medical research; Biological research; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Research and development services in the field of biotechnology; Research in the field of DNA repair technology; Providing information about medical and scientific research via a website; Biochemical research and analysis; Research and development of vaccines and medicines; Research and development in the field of biochemistry; Research and development in the field of biotechnology; Medical research in the field of rare diseases; Biochemical research; Research and development of medicines; Research and development in the pharmaceutical and biotechnology fields; Research on the subject of pharmaceuticals; Research and development of new products; Gene therapy research; Pharmaceutical research and development; Vaccine research and development; Clinical research in the field of ophthalmology; Scientific study and research in the field(s) of ophthalmology; Pharmaceutical research in the field of ophthalmology; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Development of pharmaceuticals for cell and gene therapies

Description: On-line advertising and marketing services; Regenerative medicine services; Ophthalmology services; Providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses and therapies associated with a defined set of symptoms; Providing on-line information, news and commentary in the field of health and wellness relating to ophthalmology; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals in the field of ophthalmology; Pharmaceutical drug development services; Pharmaceutical research and development; Research and development services of new pharmaceutical products; Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical research in the field of ophthalmology; Research on the subject of pharmaceuticals; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals and genetics

Description: Living biological tissue grown and regenerated ex vivo for subsequent implantation inter vivo - namely, cartilaginous tissues, collagen, ligaments and tendons and epithelial tissues; Injectable gels for use in the treatment and repair of articular joint cartilage in human; Injectable gels for use in the treatment and repair of joint cartilage; Prosthetic ligaments; Artificial ligaments; Artificial cartilage; Substitutes for cartilage; Substitutes for bones, cartilage, ligaments and tendons

Description: Gene therapy products, namely, genetically engineered tissues for transplant purposes; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases; Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant DNA for treating ocular diseases; Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration

Description: Gene therapy products, namely, genetically engineered tissues for transplant purposes; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; Gene therapy products, namely, rAAV vector for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases; Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant DNA for treating ocular diseases; Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa; Gene therapy products, namely, rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration

Description: House mark for a full line of pharmaceutical preparations; House mark for a full line of pharmaceutical preparations for vaccines and for treating diseases and disorders such as infections, eye disorders, and orthopedic diseases

Description: House mark for pharmaceutical preparations for treating diseases and disorders affecting the eye

Description: House mark for pharmaceutical preparations for treating diseases and disorders affecting the eye

Description: House mark for pharmaceutical preparations for treating diseases and disorders affecting the eye

Description: Living biological tissue grown and regenerated ex vivo for subsequent implantation inter vivo - namely, cartilaginous tissues, collagen, ligaments and tendons and epithelial tissues

Description: Living biological tissue grown and regenerated ex vivo for subsequent implantation inter vivo, namely, cartilaginous tissues, collagen, ligaments and tendons and epithelial tissues

Description: LIVING BIOLOGICAL TISSUE GROWN AND REGENERATED EX VIVO FOR SUBSEQUENT IMPLANTATION INTER VIVO - NAMELY, CARTILAGINOUS TISSUES, COLLAGEN, LIGAMENTS AND TENDONS AND EPITHELIAL TISSUES | [ BIOTECHNOLOGICAL TISSUE PROCESSOR FOR APPLYING ADJUSTABLE LEVELS OF PRESSURE, FLOW RATE AND GASES FOR GROWTH AND REGENERATION EX VIVO OF LIVING BIOLOGICAL TISSUE - NAMELY, CARTILAGINOUS TISSUES, COLLAGEN, LIGAMENTS AND TENDONS AND EPITHELIAL TISSUES ] | MEDICAL SERVICES - NAMELY, THE EX VIVO GROWTH AND REGENERATION OF LIVING BIOLOGICAL TISSUE